Lu Song

The promise and challenge of therapeutic genome editing

Determining cell type abundance and expression from bulk tissues with digital cytometry

Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects

Applications of CRISPR-Cas Enzymes in Cancer Therapeutics and Detection

Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy

Inhibition of HBV Expression in HBV Transgenic Mice Using AAV-Delivered CRISPR-SaCas9

A Pragmatic Guide to Enrichment Strategies for Mass Spectrometry–Based Glycoproteomics

Discovery of a Selective Inhibitor for the YEATS Domains of ENL/AF9

Real-space refinement in PHENIX for cryo-EM and crystallography

Single-cell transcriptomic analysis of Alzheimer’s disease

Comprehensive transcriptome analysis of neocortical layers in humans, chimpanzees and macaques

Organoid single-cell genomic atlas uncovers human-specific features of brain development

Recent Advances in Therapeutic Genome Editing in China

Chemical Inhibition of ENL/AF9 YEATS Domains in Acute Leukemia

Chemical Tagging in Mass Spectrometry for Systems Biology

Tools for the cryo-EM gold rush: going from the cryo-EM map to the atomistic model

Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors

AF9 promotes hESC neural differentiation through recruiting TET2 to neurodevelopmental gene loci for methylcytosine hydroxylation

Spatial Transcriptome for the Molecular Annotation of Lineage Fates and Cell Identity in Mid-gastrula Mouse Embryo

Genome editing with CRISPR/Cas9 in postnatal mice corrects PRKAG2 cardiac syndrome

Simultaneous quantitation of hydrazine and acetylhydrazine in human plasma by high performance liquid chromatography-tandem mass spectrometry after derivatization with p -tolualdehyde

The transcription factor Pou3f1 promotes neural fate commitment via activation of neural lineage genes and inhibition of external signaling pathways